COAG News
Archived Headlines
- Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week 04/27/26
- US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut 04/24/26
- US IPO Weekly Recap: Pipeline swells with sizable IPO filings as Metals Royalty direct lists 04/10/26
- Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO 04/10/26
US IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market
Four IPOs priced this past week, led by three sizable biotechs. They were joined by 11 blank check listings. Coagulation disorder biotech Hemab Therapeutics (COAG) upsized and priced at the high end to raise $302 million at an $849 million market cap. Hemab...read more
Renaissance Capital’s April IPO Market Update
Thirteen IPOs raised a combined $7.3 billion in April, joined by two direct listings. While surging volatility in March weighed on new issuance early on, activity ended in line with April’s 10-year historical average by deal count (15) but well above by...read more
Hemab Therapeutics prices upsized IPO at $18, the high end of the range
Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised $302 million by offering 16.8 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 11.8 million shares at ...read more
Coagulation disorder biotech Hemab Therapeutics Holdings ups shares offered by 27% ahead of $255 million IPO
Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $255 million by offering 15 million shares ...read more